Structural basis of tolvaptan binding to the vasopressin V2 receptor

Acta Pharmacol Sin. 2024 Nov;45(11):2441-2449. doi: 10.1038/s41401-024-01325-5. Epub 2024 Jun 20.

Abstract

The vasopressin V2 receptor (V2R) is a validated therapeutic target for autosomal dominant polycystic kidney disease (ADPKD), with tolvaptan being the first FDA-approved antagonist. Herein, we used Gaussian accelerated molecular dynamics simulations to investigate the spontaneous binding of tolvaptan to both active and inactive V2R conformations at the atomic-level. Overall, the binding process consists of two stages. Tolvaptan binds initially to extracellular loops 2 and 3 (ECL2/3) before overcoming an energy barrier to enter the pocket. Our simulations result highlighted key residues (e.g., R181, Y205, F287, F178) involved in this process, which were experimentally confirmed by site-directed mutagenesis. This work provides structural insights into tolvaptan-V2R interactions, potentially aiding the design of novel antagonists for V2R and other G protein-coupled receptors.

Keywords: binding pathway; gaussian accelerated molecular dynamics (GaMD) simulations; tolvaptan; vasopressin V2 receptor (V2R).

MeSH terms

  • Antidiuretic Hormone Receptor Antagonists* / chemistry
  • Antidiuretic Hormone Receptor Antagonists* / pharmacology
  • Benzazepines / chemistry
  • Benzazepines / metabolism
  • Benzazepines / pharmacology
  • Binding Sites
  • HEK293 Cells
  • Humans
  • Molecular Dynamics Simulation*
  • Mutagenesis, Site-Directed
  • Protein Binding
  • Protein Conformation
  • Receptors, Vasopressin* / chemistry
  • Receptors, Vasopressin* / metabolism
  • Tolvaptan* / chemistry
  • Tolvaptan* / metabolism
  • Tolvaptan* / pharmacology
  • Tolvaptan* / therapeutic use

Substances

  • Tolvaptan
  • Receptors, Vasopressin
  • Antidiuretic Hormone Receptor Antagonists
  • AVPR2 protein, human
  • Benzazepines